EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data

Sukru Cekic, Yakup Canitez, Deniz Ozceker, Pınar Uysal, Oner Ozdemir, Serkan Filiz, Hamit Bologur, Yasin Karali, Hale Yuksel, Nihat Sapan

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000545336 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Sukru Cekic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergy and Clinical Immunology, Bursa Uludag University School of Medicine, Bursa, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Limited data are available regarding the effectiveness of different omalizumab-dosing strategies in childhood chronic spontaneous urticaria (CSU). This study aimed to investigate the efficacy of omalizumab initiated at different doses in children and adolescents with CSU based on real-life data.

Methods

This study was conducted at five academic medical centers in Turkey. Patient data were obtained from their file data. Omalizumab treatment was initiated at a dose of 150 mg every 4 weeks in 37 (60.7%) patients (group 1) and 300 mg in 24 (39.3%) patients (group 2).

Results

The mean age of patients was 14.4 ± 2.6 years (6.3–18 years), and female-to-male ratio was 2.2 (42/19). There was no difference between the mean initial UAS7 scores of groups 1 and 2 (34 ± 8.8 and 34.6 ± 9.1, respectively) (p = 0.854). Groups 1 and 2 achieved an urticaria-free or well-controlled status at rates of 75.7% (n = 28) and 87.5% (n = 21), respectively, during the treatment period (p = 0.334). Group 2 achieved urticaria-free or well-controlled status in a shorter time than group 1 (median: 1 month [1–3 months] and median: 2 months [1–4 months], respectively) (p = 0.036). The rate of patients who achieved urticaria-free status during the study period was 59.5% (n = 22) and 87.5% (n = 21) in groups 1 and 2, respectively (p = 0.023). Seven patients in group 1 (31.8%) and 2 patients in group 2 (9.5%) experienced recurrence (p = 0.132). At the last evaluation, more patients in group 2 (83.3%, n = 20) were urticaria-free than in group 1 (48.6%, n = 18) (p = 0.008). A patient had an exacerbation of urticaria associated with omalizumab within the first 24 h of the first dose, but this complication was not repeated. Other than dizziness in 1 patient, no different side effects were seen in our cohort of patients.

Conclusion

Omalizumab is an effective and reliable treatment option for childhood CSU. Urticaria-free or well-controlled status can be achieved in a shorter time by initiating treatment with a 300 mg/4 week regimen. Although this dose may need to be increased in most cases, control can be achieved with a dose of 150 mg/4 weeks in a considerable number of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsHumansMaleFemaleAdolescentChildTreatment OutcomeTurkey

Stichwörter der Autor:innen

ChildrenChronic spontaneous urticariaOmalizumab

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Pediatric Allergy and Clinical Immunology, Bursa Uludag University School of Medicine, Bursa, Turkey.
  • Department of Pediatric Allergy and Clinical Immunology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.
  • Department of Pediatric Allergy and Clinical Immunology, Aydin Adnan Menderes University School of Medicine, Aydin, Turkey.
  • Department of Pediatric Allergy and Clinical Immunology, Sakarya University Training and Research Hospital, Adapazari, Turkey.
  • Department of Pediatric Allergy and Clinical Immunology, Antalya Training and Research Hospital, Antalya, Turkey.
  • Uludag University School of Medicine, Bursa, Turkey.

Zitieren

APA

Cekic, S., Canitez, Y., Ozceker, D., Uysal, P., Ozdemir, O., Filiz, S., Bologur, H., Karali, Y., Yuksel, H., & Sapan, N. (2025). The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data. International Archives of Allergy and Immunology. https://doi.org/10.1159/000545336

Vancouver

Cekic S, Canitez Y, Ozceker D, Uysal P, Ozdemir O, Filiz S, et al. The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data. International Archives of Allergy and Immunology. 2025. doi:10.1159/000545336

BibTeX
@article{Cekic2025,
  author = {Cekic, Sukru and Canitez, Yakup and Ozceker, Deniz and Uysal, Pınar and Ozdemir, Oner and Filiz, Serkan and Bologur, Hamit and Karali, Yasin and Yuksel, Hale and Sapan, Nihat},
  title = {The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000545336}
}
Kostenlos starten →